vg
sequenc
peptid
either
unconjug
conjug
cholesterol
cterminu
linker
length
rang
peg
assess
abil
inhibit
cellcel
fusion
mediat
viral
glycoprotein
quantit
cellcel
fusion
assay
base
complement
use
previous
cholesterol
conjug
improv
peptid
inhibit
cellcel
fusion
mediat
niv
glycoprotein
expect
incorpor
spacer
significantli
enhanc
peptid
efficaci
viral
glycoprotein
increas
linker
length
improv
upon
result
peptid
longest
spacer
test
highest
potenc
assay
niv
glycoprotein
fig
suggest
relationship
spacer
size
efficaci
inhibit
fusion
linear
impact
orient
peptid
sequenc
abil
block
cellcel
fusion
explor
fig
conjug
lipid
moieti
peg
spacer
either
cterminu
eg
vgchol
nterminu
eg
cholvg
conjug
peptid
show
potenc
assay
ntermin
conjug
peptid
significantli
effect
block
fusion
niv
contrast
cholvg
littl
effect
determin
niv
fusion
ctermin
conjug
peptid
block
niv
glycoproteinmedi
fusion
high
efficaci
presenc
peg
linker
efficaci
hrcderiv
peptid
higher
spacer
lipid
conjug
ntermin
result
loss
multipot
niv
result
suggest
orient
peptid
sequenc
length
spacer
import
antivir
multipot
previou
studi
use
hrcderiv
lipidconjug
peptid
investig
conform
flexibl
uncleav
f
protein
f
precursor
protein
form
hydrophob
fusion
domain
still
buri
peptid
bind
correspond
hrn
domain
expos
unfold
f
serv
tool
identifi
exposur
experi
peptid
attach
red
blood
cell
rbc
membran
via
cholesterol
tail
rbc
allow
interact
cell
express
uncleav
mutant
f
along
hn
engag
sialic
acid
receptor
rbc
initi
factiv
readout
peptid
interact
f
protein
hrn
adher
rbc
fexpress
cell
sinc
uncleav
f
insert
rbc
membran
adher
occur
via
peptid
bridg
form
peptid
anchor
rbc
via
lipid
tail
also
interact
hrn
sequenc
f
express
transfect
uncleav
f
enough
flexibl
unfold
expos
hrn
domain
upon
activ
hn
fulli
extend
transient
prehairpin
intermedi
hydrophob
end
insert
target
explor
peptid
function
assay
provid
measur
effici
peptid
bind
earli
stage
fusion
process
finsert
step
use
peptid
bridg
assay
assess
interact
seri
modifi
vg
peptid
earli
transit
step
f
protein
fig
cell
coexpress
hn
uncleav
f
cleavag
site
mutant
csm
allow
interact
receptorbear
rbc
transfer
presenc
either
ctermin
ntermin
conjug
peptid
without
linker
zanamivir
sialic
acid
analog
block
hnreceptor
ad
h
disengag
cell
bound
hnreceptor
engag
alon
proport
rbc
either
free
revers
bound
hnreceptor
interact
therefor
releas
zanamivir
irrevers
bound
peptid
bridg
fuse
quantifi
unconjug
vg
ntermin
conjug
cholvg
peptid
fail
bind
hrc
uncleav
f
manner
suffici
bridg
fexpress
cell
receptorbear
cell
rbc
free
revers
bound
attach
hnreceptor
engag
presenc
contrast
vgchol
ctermin
lipid
conjug
peptid
bridg
cell
popul
attach
f
protein
plasma
membran
rbc
suggest
irrevers
bound
rbc
presenc
peptid
peg
spacer
peptid
led
increas
bridg
seen
irrevers
rbc
bind
ctermin
ntermin
conjug
peptid
ctermin
conjug
peptid
significantli
effect
interact
earli
transit
intermedi
f
sinc
spacerless
cholvg
fail
bridg
result
suggest
spacer
permit
ntermin
conjug
peptid
insert
rbc
membran
peptid
test
show
effect
bridg
irrevers
retent
peptid
effect
inhibit
fusion
inhibit
fig
look
similar
vgchol
far
less
effect
inhibitor
explor
may
relat
dynam
membran
insert
allow
releas
bridg
mediat
peptid
releas
attach
rbc
aggreg
lipidbind
properti
vg
peptid
assess
base
intrins
fluoresc
tryptophan
trp
residu
fig
fluoresc
excit
spectra
vg
peptid
buffer
nearli
overlap
free
trp
regard
fluoresc
emiss
spectra
untag
peptid
vg
show
close
overlap
trp
spectrum
cholesterolcontain
vg
peptid
present
blueshift
emiss
maximum
indic
trp
residu
conjug
hydrophob
environ
previous
observ
differ
cholesteroltag
hiv
fusion
inhibitor
fusion
inhibitor
aggreg
propens
test
use
fluoresc
dye
sulfon
an
presenc
hydrophob
pocket
signific
increas
an
quantum
yield
blueshift
maximum
emiss
peak
observ
expect
untag
peptid
vg
unabl
form
aggreg
fig
titrat
an
vgchol
led
signific
blueshift
nm
nm
nm
respect
data
shown
indic
cholesteroltag
peptid
form
aggreg
dissolv
hepe
mm
nacl
mm
buffer
vgchol
compar
order
test
peg
spacer
effect
peptid
aggreg
fig
longer
peg
spacer
lower
aggreg
observ
variat
evid
upon
compar
vgchol
fig
quantifi
peptidemembran
affin
assess
chang
induc
cholesterol
conjug
evalu
abil
vg
seri
peptid
induc
chang
surfac
pressur
lipid
monolay
fig
shown
fig
vg
peptid
abl
induc
chang
surfac
pressur
popc
monolay
vg
peptid
solvent
control
dimethyl
sulfoxid
dmso
show
chang
lipid
monolay
activ
peptid
induc
largest
chang
monolay
surfac
pressur
mnm
fig
increas
concentr
vg
peptid
led
increas
surfac
pressur
plateau
peptid
satur
monolay
reach
data
allow
use
equat
calcul
dissoci
constant
kd
despit
similar
affin
popc
fig
vg
peptid
present
distinct
kinet
toward
lipid
fig
use
equat
higher
insert
rate
k
observ
comparison
vgchol
fig
similar
kinet
behavior
observ
mixtur
popc
cholesterol
repres
order
domain
membran
cell
high
cholesterol
content
rbc
data
shown
rbc
select
cell
model
test
peptidecel
membran
affin
howev
direct
measur
peptid
tryptophan
fluoresc
impractic
cell
indirect
report
use
lipophil
fluoresc
probe
measur
interact
peptid
cell
membran
rbc
label
probe
previous
vg
peptid
incub
rbc
h
cholesteroltag
peptid
abl
induc
chang
membran
dipol
potenti
sens
fig
vg
peptid
control
dmso
caus
chang
membran
dipol
potenti
quantit
measur
interact
vg
peptid
membran
ratio
r
measur
rang
peptid
concentr
ratio
decreas
upon
increas
concentr
cholesteroltag
peptid
follow
hyperbol
curv
curv
fit
equat
allow
determin
dissoci
constant
kd
show
higher
affin
kd
comparison
vgchol
kd
kd
fig
recent
test
hypothesi
lipid
conjug
decreas
proteas
sensit
addit
peg
linker
increas
proteas
sensit
figur
show
vg
seri
peptid
incub
absenc
presenc
trypsin
hr
cholesterol
conjug
vg
decreas
proteas
degrad
compar
panel
lane
lane
ad
linker
cholesterol
cterminu
increas
degrad
significantli
panel
b
lane
howev
cholesterol
without
peg
linker
conjug
nterminu
peptid
significantli
resist
proteas
degrad
panel
c
show
even
peptid
ntermin
tag
degrad
explor
signific
observ
context
authent
viru
assess
efficaci
vg
seri
peptid
inhibit
infect
live
niv
cell
cultur
fig
expect
cholesterol
conjug
significantli
amelior
peptid
efficaci
virus
measur
reduct
plaqu
format
presenc
linker
impact
peptid
nm
reduc
inhibit
niv
nm
nm
increas
spacer
length
led
signific
increas
efficaci
nm
niv
nm
addit
evalu
toxic
specif
peptid
tabl
show
toxic
cell
appear
reach
concentr
nm
toxic
peptid
seri
even
lower
sinc
although
quit
nontox
highest
toxic
peptid
seri
chose
peptid
experi
design
assess
specif
inhibit
compar
antivir
effect
conjug
peptid
effect
measl
influenza
viru
felin
immunodefici
viru
none
peptid
inhibitori
support
notion
potenc
depend
presenc
peptid
sequenc
simpli
linker
lipid
moieti
tabl
hae
cultur
authent
model
human
lung
use
evalu
featur
infect
antivir
efficaci
peptid
efficaci
hae
seem
correl
vivo
therefor
assess
efficaci
vg
peptid
hae
use
authent
lung
model
compar
peptid
best
potenc
monolay
cultur
toxic
concentr
hae
cultur
compar
abil
inhibit
infect
hae
singl
dose
decreas
viral
titer
approxim
two
log
day
infect
approxim
one
log
day
viru
produc
time
infect
indic
viral
infect
complet
inhibit
concentr
hae
inhibitor
given
singl
dose
result
complet
inhibit
infect
howev
show
partial
inhibit
data
shown
util
peptid
antivir
depend
larg
part
biodistribut
avail
site
infect
previous
assess
biodistribut
deriv
peptid
hamster
cotton
rat
serv
model
niv
assess
halflif
distribut
peptid
mgkg
ip
detect
free
peptid
serum
h
concentr
peak
nm
drop
h
accompani
peptid
detect
h
organ
fig
peptid
detect
urin
suggest
peptid
elimin
intact
data
shown
immunohistofluoresc
show
peptid
present
brain
parenchyma
h
administr
confirm
abil
reach
cn
fig
c
previous
observ
cn
local
also
measl
viru
mv
f
sequenc
deriv
suggest
featur
requir
highli
specif
peptid
sequenc
establish
peptid
biodistribut
cotton
rat
hamster
assess
efficaci
niv
infect
correspond
model
peptid
administ
sq
significantli
decreas
viral
load
cotton
rat
lung
day
intranas
infect
p
use
mannwhitney
utest
fig
niv
ip
peptid
administr
daili
day
niv
inocul
ip
significantli
improv
surviv
hamster
given
lethal
infect
inoculum
p
use
mantelcox
test
fig
result
suggest
peptid
identifi
bear
optim
biophys
properti
vitro
inhibit
promis
inhibitor
infect
effect
virus
vivo
shown
specif
predict
featur
import
paramyxoviru
antivir
peptid
efficaci
begun
pinpoint
contribut
efficaci
amino
acid
sequenc
lipid
moieti
well
linker
length
solubl
biophys
featur
build
upon
remark
foundat
peptid
sequenc
deriv
hrc
domain
one
paramyxoviru
inhibit
quit
differ
paramyxoviru
niv
fluoresc
spectra
vg
seri
peptid
fig
show
conjug
cholesterol
lead
chang
microenviron
fluoresc
tryptophan
residu
result
indic
hydrophob
set
surround
tryptophan
suggest
possibl
peptid
aggreg
data
an
experi
fig
confirm
hypothesi
show
incorpor
vg
seri
peptid
partial
decreas
aggreg
recent
work
pegyl
report
conjug
peg
peptid
enhanc
peptid
solubl
led
concentrationdepend
revers
longer
peg
linker
promot
faster
kinet
toward
lipid
monolay
observ
fig
addit
presenc
cholesterol
length
linker
also
key
factor
contribut
membran
drive
forc
agreement
previou
result
less
aggreg
peptid
could
diffus
easili
toward
cell
membran
benefici
peptid
local
concentr
high
affin
rbc
membran
observ
fig
corrobor
lipid
monolay
aggreg
experi
previous
shown
cholesterol
conjug
fusion
inhibitor
peptid
also
promot
interact
peptid
lack
membran
bind
domain
optim
candid
cholesterol
tag
antivir
activ
boost
inclus
peg
spacer
seem
reduc
peptid
aggreg
induc
fast
kinet
toward
cell
membran
correl
biophys
analys
antivir
activ
data
suggest
synerg
combin
effect
membranotrop
behavior
provid
cholesterol
addit
increas
solubl
decreas
tendenc
aggreg
confer
peg
addit
explain
antivir
pattern
found
compound
optim
peptid
must
correct
balanc
membran
tropism
solubl
effect
peptid
test
niv
fastest
kinet
insert
releas
membran
featur
correl
peg
linker
length
howev
long
peg
linker
expect
caus
peptid
expos
aqueou
sensit
proteas
degrad
shown
fig
therebi
shorter
halflif
word
seem
sinc
pocket
bind
domain
antivir
peptid
expos
potent
also
sensit
proteas
could
potenti
explain
level
brain
serum
rel
low
compar
previou
data
find
longer
peg
increas
proteas
sensit
part
complex
identifi
ideal
candid
vivo
test
one
must
identifi
balanc
absolut
antivir
potenc
stabil
order
abl
take
advantag
antivir
potenc
confer
longer
linker
address
way
reduc
proteas
sensit
exampl
modifi
protein
backbon
surprisingli
cholesterol
without
peg
linker
conjug
nterminu
peptid
significantli
resist
proteas
degrad
fig
lipid
conjug
known
enhanc
helic
specul
differenti
effect
conjug
n
ctermini
may
relat
fact
nterminu
peptid
less
structur
therefor
like
proteas
sensit
conjug
lessstructur
terminu
may
therebi
protect
either
due
effect
aggreg
enhanc
helic
focus
antivir
strategi
peptid
lipid
conjug
cterminu
far
potent
inhibitor
compar
lipid
conjug
show
ad
peg
linker
lipid
peptid
sequenc
nterminu
ntermin
conjug
peptid
render
potent
viru
deriv
efficaci
ntermin
lipid
conjug
fusion
inhibitori
peptid
studi
newcastl
diseas
case
newcastl
diseas
viru
li
et
al
show
ntermin
cholesterol
conjug
enhanc
potenc
inhibitori
peptid
allow
penetr
cn
effect
addit
linker
ntermin
cholesterol
inhibitori
peptid
less
clear
case
linker
ntermin
cholesterol
peptid
significantli
enhanc
potenc
abrog
broadspectrum
antivir
activ
specul
without
flexibl
linker
ntermin
conjug
peptid
could
attain
proper
posit
interact
target
region
f
could
anchor
membran
later
fusion
process
fusion
peptid
insert
refold
step
mechanist
basi
neg
effect
inhibit
niv
remain
explor
shown
schemat
fig
flexibl
peg
linker
allow
freedom
orient
order
align
properli
target
hrn
domain
dynam
kinet
insert
membran
may
advantag
interact
f
protein
insert
host
cell
membran
point
target
lipidconjug
unconjug
peptid
inhibitor
also
interact
preinsert
f
preinsert
f
protein
shown
fig
extend
transient
intermedi
panel
panel
b
c
depict
ctermin
conjug
vgchol
peptid
linker
length
interact
preinsert
step
fusion
suggest
longer
linker
may
allow
optim
align
peptid
hrn
f
peptid
linker
fig
e
shown
effect
inhibitor
less
potent
captur
earli
intermedi
f
activ
see
fig
base
biophys
data
show
increas
dynam
membran
interact
peptid
specul
peptid
may
flip
target
host
cell
panel
viral
membran
panel
e
reduc
observ
captur
f
increas
efficaci
mechan
could
also
explain
ntermin
conjug
peptid
may
render
effect
long
linker
could
either
optim
align
f
permit
activ
cell
viral
surfac
studi
focus
peptid
lipid
conjug
cterminu
approach
led
conserv
broad
antivir
spectrum
primari
goal
work
howev
light
advantag
shown
ntermin
conjug
peptid
term
proteas
sensit
also
explor
effect
longer
peg
linker
potenc
proteas
sensit
nlink
peptid
determin
basi
differ
antivir
spectrum
confer
orient
lipid
moieti
futur
studi
address
issu
proteas
sensit
addit
vari
locat
lipophil
moieti
modifi
amino
acid
backbon
render
less
proteas
sensit
biophys
data
shown
lead
sever
conclus
appli
peptid
design
lipid
moieti
drive
interact
peptid
lipid
membran
determin
affin
compound
toward
membran
cholesterol
moieti
conserv
among
activ
compound
assess
may
explain
similar
dissoci
constant
obtain
differ
molecul
howev
observ
signific
differ
kinet
behavior
peptid
exhibit
fastest
kinet
membran
insert
follow
addit
cholesterol
lipid
monolay
boost
kinet
rate
constant
peptid
potent
peptid
interact
well
membran
absenc
cholesterol
target
membran
data
shown
specul
linear
membranotrop
associationdissoci
membran
properti
associ
effect
peptid
also
affect
biodistribut
therefor
vivo
efficaci
may
circul
associ
rbc
assess
serum
rbc
peptidedos
anim
found
peptid
present
plasma
surfac
rbc
data
shown
associ
rbc
may
one
mechan
wherebi
lipid
moieti
enhanc
halflif
vivo
addit
peg
linker
significantli
enhanc
potenc
confer
proteas
sensit
issu
may
mitig
measur
includ
ntermin
conjug
understand
set
properti
correl
peptid
potenc
permit
enhanc
antivir
effect
peptid
niv
addit
guid
peptid
design
principl
use
obtain
optim
balanc
orient
lipid
moieti
valenc
linker
length
amino
acid
sequenc
goal
broad
spectrum
activ
paramyxovirus
human
kidney
epitheli
vero
cell
obtain
atcc
grown
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
antibiot
cell
test
neg
mycoplasma
mycoplasma
detect
kit
lonza
peptid
produc
standard
fmocsolid
phase
method
cholesterol
moieti
attach
peptid
via
chemoselect
reaction
thiol
group
extra
cystein
residu
ad
ctermin
sequenc
bromoacetyl
deriv
cholesterol
previous
clinic
isol
viru
ci
obtain
clinic
microbiolog
laboratori
new
york
presbyterian
hospit
grown
human
airway
epithelium
hae
airliquid
interfac
one
passag
prior
use
experi
recombin
viru
express
use
cotton
rat
experi
obtain
ursula
buchholz
peter
collin
niaid
pseudotyp
virus
gener
use
recombin
vsv
deriv
cdna
vsv
indiana
g
gene
replac
dsred
gene
rfp
pseudotyp
niv
f
g
gener
describ
briefli
cell
transfect
plasmid
encod
vsvg
nivfg
five
hour
posttransfect
dish
wash
infect
multipl
infect
moi
complement
vsvg
supernat
fluid
contain
pseudotyp
viru
niv
fg
vsvg
collect
h
postinfect
store
niv
isol
cerebrospin
fluid
patient
receiv
dr
kb
chua
dr
sk
lam
univers
malaya
kuala
lumpur
malaysia
niv
prepar
infect
cell
previous
inserm
jean
biosafeti
level
laboratori
lyon
franc
previous
adapt
fusion
assay
base
alpha
complement
assay
receptorbear
cell
express
omega
peptid
mix
cell
coexpress
envelop
glycoprotein
alpha
peptid
cell
fusion
lead
alphaomega
complement
fusion
stop
lyse
cell
addit
substrat
tropix
chemiluminesc
report
assay
system
appli
biosystem
fusion
quantifi
spectramax
micropl
reader
overnight
fusion
assay
cell
express
alpha
omega
peptid
cocultur
h
describ
nivfg
glycoprotein
pseudotyp
onto
result
pseudotyp
virus
use
infect
niv
fgexpress
cell
moi
simul
multicycl
replic
rfp
product
h
analyz
micropl
fluoresc
reader
spectramax
detect
rfp
express
level
well
read
excit
emiss
detect
yfp
express
well
read
excit
emiss
modifi
multicycl
replic
assay
vsv
g
glycoprotein
pseudotyp
onto
result
pseudotyp
virus
use
infect
viral
glycoprotein
express
cell
simul
multicycl
replic
singlecycl
infect
assay
vsvg
pseudotyp
use
moi
infect
cell
transfect
control
plasmid
monolay
cell
transfect
transient
express
cleavag
site
mutant
f
wt
hn
presenc
neuraminidas
muml
overnight
next
day
cell
wash
incub
neuraminidas
muml
cyclohexamid
h
cell
wash
incub
rbc
suspens
independ
medium
life
technolog
ph
min
rins
remov
unbound
rbc
independ
medium
peptid
ad
plate
place
h
zanamivir
ad
final
concentr
mm
plate
left
complet
releas
rbc
nontreat
sampl
plate
rock
liquid
phase
collect
vbottom
tube
measur
releas
rbc
monolay
incub
ml
rbc
lysi
solut
lysi
unfus
rbc
remov
rbc
whose
membran
fuse
hnfcoexpress
cell
liquid
phase
collect
vbottom
plate
measur
revers
bound
rbc
cell
lyse
triton
salin
pb
transfer
flatbottom
plate
quantif
pool
fuse
rbc
amount
rbc
three
compart
describ
determin
measur
absorpt
nm
popc
purchas
avanti
polar
lipid
alabast
al
usa
cholesterol
chol
sigma
vg
peptid
contain
one
tryptophan
residu
intrins
fluoresc
make
fluoresc
spectroscopi
methodolog
suitabl
tool
follow
molecul
membran
dipol
potenti
studi
carri
varian
cari
eclips
fluoresc
spectrophotomet
mulgrav
australia
peptid
aggreg
studi
evalu
seri
fluoresc
spectrophotomet
edinburgh
instrument
livingston
uk
ltryptophan
hepe
nacl
merck
darmstadt
germani
work
buffer
use
throughout
studi
hepe
mm
ph
nacl
intrins
fluoresc
measur
vg
peptid
tryptophan
sake
comparison
perform
excit
wavelength
nm
start
emiss
wavelength
nm
excit
spectra
speci
obtain
nm
fix
emiss
wavelength
nm
an
fluoresc
emiss
spectra
obtain
nm
excit
wavelength
nm
typic
spectral
bandwidth
nm
excit
nm
emiss
excit
emiss
spectra
correct
wavelengthdepend
instrument
emiss
also
correct
success
dilut
scatter
simultan
light
absorpt
quencher
fluoresc
measur
perform
approxim
effect
peptid
concentr
vg
vgchol
aggreg
follow
an
excit
nm
intens
fluoresc
emiss
collect
mn
final
an
concentr
use
throughout
experi
titrat
peptid
stock
solut
yield
final
peptid
concentr
rang
wayanova
statist
analysi
appli
distinguish
influenc
peg
linker
peptid
aggreg
chang
surfac
pressur
lipid
monolay
induc
vg
vgchol
measur
langmuirblodgett
trough
nima
coventri
uk
constant
temperatur
briefli
solut
lipid
chloroform
spread
teflon
trough
fix
area
reach
surfac
pressur
mnm
lipid
use
studi
form
monolay
upon
spread
interfac
peptid
solut
inject
subphas
chang
surfac
pressur
follow
time
necessari
reach
constant
valu
surfac
pressur
airwat
interfac
upon
inject
largest
concentr
peptid
use
throughout
studi
alway
mnm
data
shown
reason
lowest
initi
surfac
pressur
lipid
monolay
addit
peptid
subphas
valu
condit
chang
surfac
pressur
observ
upon
inject
peptid
attribut
effect
peptid
monolay
interfaci
tension
dissoci
constant
kd
calcul
adsorpt
langmuir
isotherm
chang
surfac
pressur
maximum
chang
pressur
achiev
peptid
peptid
concentr
insert
rate
constant
k
calcul
isol
rbc
human
blood
sampl
approv
joint
ethic
committe
faculdad
de
medicina
da
universidad
de
lisboa
hospit
de
santa
maria
sampl
obtain
healthi
volunt
instituto
sangu
lisbon
portug
patient
provid
written
inform
consent
enrol
studi
addit
method
perform
accord
relev
guidelin
regul
rbc
label
membran
dipol
potenti
sensit
probe
invitrogen
carlsbad
ca
usa
briefli
blood
sampl
centrifug
g
min
plasma
buffycoat
remov
remain
rbc
wash
twice
hepe
buffer
rbc
hematocrit
incub
buffer
supplement
mv
pluron
sigma
unbound
probe
label
cell
wash
pluronicfre
buffer
two
centrifug
cycl
vg
vgcholesterol
incub
erythrocyt
hematocrit
h
gentl
agit
fluoresc
measur
excit
spectra
ratio
intens
excit
wavelength
nm
r
obtain
emiss
set
nm
order
avoid
membran
fluidityrel
excit
emiss
slit
measur
set
nm
respect
variat
r
peptid
concentr
analyz
singl
bind
site
r
valu
normal
valu
absenc
peptid
rmin
defin
asymptot
minimum
valu
r
kd
appar
dissoci
constant
peptid
activ
determin
plaqu
reduct
assay
infect
cell
inhibit
calcul
use
graph
pad
prism
softwar
data
express
mean
standard
deviat
sd
n
separ
experi
plaqu
reduct
assay
serial
dilut
peptid
dulbecco
modifi
eagl
medium
dmem
invitrogen
ad
report
cell
monolay
vero
cell
wellplat
cellswel
h
pfu
niv
ad
supernat
fluid
vero
cell
cultur
incub
h
supernat
fluid
replac
ml
carboxymethylcellulos
dmem
contain
fc
plate
incub
day
plate
develop
use
central
plaqu
assay
previous
inhibit
calcul
use
graph
pad
prism
softwar
data
express
mean
sd
n
separ
experi
vero
cell
seed
plate
densiti
cellswel
dmem
gibco
supplement
fc
mm
lglutamin
allow
form
confluent
monolay
overnight
humidifi
atmospher
cell
cultur
incub
absenc
presenc
serial
dilut
peptid
cell
viabil
determin
hr
mtt
method
mtt
cell
prolifer
assay
kit
epiairway
system
mattek
corpor
consist
normal
humanderiv
tracheobronchi
epitheli
cell
cultur
form
pseudostratifi
highli
differenti
mucociliari
epithelium
close
resembl
epitheli
tissu
vivo
upon
receipt
manufactur
hae
cultur
transfer
plate
contain
ml
medium
per
well
apic
surfac
remain
expos
air
incub
hae
cultur
infect
appli
epiairway
medium
contain
pfu
without
peptid
apic
surfac
min
medium
contain
inoculum
remov
cultur
place
fed
day
ml
medium
via
basolater
surfac
virus
harvest
ad
medium
per
well
hae
cultur
apic
surfac
allow
equilibr
min
suspens
collect
viral
titer
determin
previous
viral
collect
perform
sequenti
well
cell
day
post
infect
trypsin
digest
peptid
treat
trypsin
pb
peptid
solut
incub
minut
follow
incub
laemmli
sd
reduc
buffer
ad
solut
sampl
boil
minut
run
tricin
gel
v
gel
allow
fix
overnight
glutaraldehyd
pb
gel
stain
use
silver
stain
kit
cat
week
old
femal
syrian
golden
hamster
anim
per
group
intraperiton
inject
peptid
mgkg
water
inject
aguett
time
point
blood
collect
edta
vacutain
tube
anim
correspond
group
tube
centrifug
min
rpm
plasma
transfer
new
tube
conserv
use
elisa
h
organ
anim
collect
separ
two
one
half
conserv
elisa
half
frozen
cold
isopentan
dri
ice
place
cryosect
anim
bred
anim
facil
umdnj
newark
protocol
approv
institut
anim
care
use
committe
iacuc
approv
protocol
amend
experi
perform
accord
relev
guidelin
regul
frozen
organ
weigh
mix
pb
wv
use
ultra
turrax
homogen
sampl
treat
acetonitriletfa
vv
h
wheel
centrifug
min
rpm
supernat
fluid
collect
elisa
well
plate
maxisorp
nunc
coat
overnight
purifi
goat
f
hrc
antibodi
carbonatebicarbon
buffer
ph
plate
wash
twice
pb
block
pb
min
block
buffer
replac
dilut
sampl
pb
duplic
incub
h
room
temperatur
rt
well
wash
time
pb
develop
purifi
rabbit
f
hrc
antibodi
conjug
peroxidas
pb
h
rt
follow
wash
incub
sigmafast
opd
substrat
system
sigmaaldrich
franc
stop
sulfur
acid
optic
densiti
read
nm
cryosect
dri
min
fix
formalin
solut
multipl
wash
pb
satur
perform
use
fb
min
rt
incub
specif
rabbit
f
hrc
antibodi
overnight
fb
multipl
wash
tissu
section
incub
secondari
goat
antirabbit
antibodi
conjug
alexa
fb
h
rt
nuclei
counterstain
dapi
multipl
wash
pb
mount
perform
use
fluoroprep
brain
section
analyz
use
axioplan
imag
microscop
zeiss
eightweekold
femal
syrian
golden
hamster
mesocricetu
auratu
janvier
franc
randomli
distribut
cage
anim
care
taker
anesthet
infect
intraperiton
ip
ml
niv
condit
group
anim
treat
daili
ip
inject
peptid
mgkg
day
start
day
infect
receiv
vehicl
untreat
group
without
formal
random
anim
follow
daili
week
blind
fashion
inbr
cotton
rat
obtain
harlan
indianapoli
femal
anim
week
age
randomli
distribut
cage
anim
care
taker
acclimat
one
week
cage
cotton
rat
group
without
formal
random
treatment
group
infect
pfu
intranas
previous
group
anim
infect
indic
viru
treat
sq
mgkgday
peptid
dose
per
day
day
day
infect
group
size
base
power
analysi
determin
differ
treatment
least
one
viral
titer
viral
titer
determin
day
post
infect
previous
sampl
exclud
analysi
signific
varianc
group
detect
sampl
analyz
blind
fashion
anim
work
approv
institut
anim
care
use
committe
ohio
state
univers
perform
accord
relev
guidelin
regul
data
normal
distribut
equal
varianc
data
describ
mean
sd
unless
otherwis
state
peptid
aggreg
experi
anova
analysi
perform
distinguish
differ
peptid
concentr
bonferroni
posttest
perform
compar
replic
mean
statist
analysi
perform
vivo
experi
comparison
viral
titer
cotton
rat
lung
base
nonparametr
utest
mantelcox
analysi
comparison
surviv
curv
niv
infect
golden
hamster
data
statist
test
perform
prism
graphpad
softwar
la
jolla
ca
cite
articl
mathieu
c
et
al
broad
spectrum
antivir
activ
paramyxovirus
modul
biophys
properti
fusion
inhibitori
peptid
sci
rep
doi
publish
note
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
